MX2022008213A - Anticuerpos anti dimero d recombinantes, procedimientos y utilizaciones de los mismos. - Google Patents

Anticuerpos anti dimero d recombinantes, procedimientos y utilizaciones de los mismos.

Info

Publication number
MX2022008213A
MX2022008213A MX2022008213A MX2022008213A MX2022008213A MX 2022008213 A MX2022008213 A MX 2022008213A MX 2022008213 A MX2022008213 A MX 2022008213A MX 2022008213 A MX2022008213 A MX 2022008213A MX 2022008213 A MX2022008213 A MX 2022008213A
Authority
MX
Mexico
Prior art keywords
dimer
recombinant antibodies
methods
fragment
fdp
Prior art date
Application number
MX2022008213A
Other languages
English (en)
Inventor
Jody Berry
Elizabeth A Booth
Charles Holz
Tristan Wasley
Virginia Montanini
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2022008213A publication Critical patent/MX2022008213A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Esta solicitud se refiere a anticuerpos anti dímero D recombinantes que se unen de forma específica a fibrina y a los productos de degradación del fibrinógeno (FDP) tales como dímero D, fragmento DD y fragmento D con alta afinidad de unión y no se unen al fragmento E y al fibrinógeno. La presente invención también se refiere a procedimientos y ensayos para la detección de dímero D y fragmentos de FDP en muestras que utilizan dichos anticuerpos recombinantes.
MX2022008213A 2020-02-20 2021-02-19 Anticuerpos anti dimero d recombinantes, procedimientos y utilizaciones de los mismos. MX2022008213A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062979253P 2020-02-20 2020-02-20
PCT/IB2021/051438 WO2021165914A1 (en) 2020-02-20 2021-02-19 Anti d-dimer recombinant antibodies, methods and uses thereof

Publications (1)

Publication Number Publication Date
MX2022008213A true MX2022008213A (es) 2022-08-04

Family

ID=74797978

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022008213A MX2022008213A (es) 2020-02-20 2021-02-19 Anticuerpos anti dimero d recombinantes, procedimientos y utilizaciones de los mismos.

Country Status (11)

Country Link
US (1) US20230082465A1 (es)
EP (1) EP4107181A1 (es)
JP (1) JP2023514952A (es)
KR (1) KR20220143834A (es)
CN (1) CN115135670A (es)
AR (1) AR121388A1 (es)
AU (1) AU2021222426A1 (es)
BR (1) BR112022013217A2 (es)
CA (1) CA3163437A1 (es)
MX (1) MX2022008213A (es)
WO (1) WO2021165914A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113717285B (zh) * 2021-11-04 2022-02-01 北京沃森赛瑟生物技术有限公司 抗人d-二聚体抗体及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013709A1 (en) * 2005-07-29 2007-02-01 Biobud Co., Ltd. Monoclonal antibody against d-dimer and diagnosis agent for detecting d-dimer, crosslinked fibrin and its derivatives containing d-dimer by using the antibody
US8940489B2 (en) * 2005-07-29 2015-01-27 Hyun-Ju Doh Monoclonal antibody against D-dimer and diagnosis agent for detecting D-dimer, crosslinked fibrin and its derivatives containing D-dimer by using the antibody
US9206250B2 (en) * 2010-04-01 2015-12-08 Lsi Medience Corporation Monoclonal antibodies and method of immunological analysis of D-dimer

Also Published As

Publication number Publication date
WO2021165914A1 (en) 2021-08-26
KR20220143834A (ko) 2022-10-25
EP4107181A1 (en) 2022-12-28
AU2021222426A1 (en) 2022-07-21
BR112022013217A2 (pt) 2022-09-13
AR121388A1 (es) 2022-06-01
JP2023514952A (ja) 2023-04-12
US20230082465A1 (en) 2023-03-16
CA3163437A1 (en) 2021-08-26
CN115135670A (zh) 2022-09-30

Similar Documents

Publication Publication Date Title
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
MX2020001227A (es) Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
MA49599A1 (fr) Anticorps spécifiques à cd47 et pd-l1
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
WO2005026209A3 (en) Monoclonal antibodies against hmgb1
AR060017A1 (es) Composiciones y metodos de uso para anticuerpos de dickkopf -1
WO2015006337A3 (en) Compositions and methods for increasing protein half-life in a serum
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
EA201891990A1 (ru) Слитые белки на основе рекомбинантного фоллистатина и fc-фрагмента и их применение в лечении мышечной дистрофии дюшенна
WO2022051591A3 (en) Nectin-4 antibodies and uses thereof
MX2022008213A (es) Anticuerpos anti dimero d recombinantes, procedimientos y utilizaciones de los mismos.
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
PH12020551373A1 (en) Anti-phf-tau antibodies and uses thereof
MX2021009275A (es) Moleculas de union especificas.
WO2022108976A3 (en) Anti-gpa33 multi-specific antibodies and uses thereof
BR112022004603A2 (pt) Anticorpo anti-cd371 ou um fragmento de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico, vetor de expressão, célula hospedeira, métodos e kit
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
BR112023000603A2 (pt) Proteínas sars-cov-2, anticorpos anti-sars-cov-2 e métodos de uso dos mesmos
MX2020007444A (es) Metodos para la cuantificacion de polipeptidos.
WO2020252394A3 (en) Targets and methods of diagnosing, monitoring and treating frontotemporal dementia
WO2023122647A3 (en) Methods for detecting or treating influenza infections
EA202192729A1 (ru) Разработка антитела для селективного в отношении опухоли связывания cd47
MX2022011801A (es) Anticuerpos monoclonales contra acidos nucleicos modificados quimicamente y usos de los mismos.